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Brian T. Hill,1 Brian J. Bolwell,1 Lisa Rybicki,2 Robert Dean,1 Matt Kalaycio,1 Brad Pohlman,1
Shawnda Tench,2 Ronald Sobecks,1 Steven Andresen,1 Edward Copelan1Allogeneic hematopoietic stem cell transplantation (SCT) for patients who have previously undergone allo-
geneic or autologous SCT is potentially curative, but dangerous. To identify patient, disease, and treatment
characteristics associated with outcome, we analyzed prognostic factors in 98 consecutive patients who un-
derwent second transplants using allogeneic donors at the Cleveland Clinic between May 1987 and October
2008. Inclusion criteria included age $18 years, first SCTeither autologous or allogeneic, and second SCT
allogeneic. Patients whose second transplant was myeloablative (MA) had shorter survival (median 3.2 versus
14.7 months, P\.001) than patients whose second transplant was nonmyeloablative (NMA). In multivariable
analysis, MA second transplant was associated with a higher risk of NRM (hazard ratio [HR] 2.01, P5 0.022)
and death (HR 2.13, P 5 0.002). Improved survival after NMA second transplant occurred primarily in pa-
tients without acute leukemia and when the first transplant was autologous. Among 17 patients transplanted
within 3 months of first transplant, mortality was 100% and median survival was 2.3 months. MA transplan-
tation within 3 months of prior SCT carries an unacceptably high rate of NRM. NMA second transplants
were associated with substantially less NRM and despite a higher incidence of relapse, significantly
improved survival compared to MA second transplants.
Biol Blood Marrow Transplant 16: 1738-1746 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Myeloablative, Nonmyeloablative, Allogeneic, Autologous, Stem cell Transplant, Bone mar-
row TransplantINTRODUCTION
Despite recent advances, following hematopoietic
stem cell transplantation (SCT), many patients will
develop disease relapse, graft failure, or treatment-
relatedmyelodysplastic sydrome [1]. Performing a sec-
ond allogeneic SCT represents the only curative
treatment in these circumstances, but it is dangerous
for patients who have previously undergone either
allogeneic or autologous SCT.
A number of retrospective series have examined
outcomes of second transplant for patients with1Hematologic Oncology and Blood Disorders, Cleveland
Taussig Cancer Institute, Cleveland, Ohio; and 2Quanti-
Health Sciences, Cleveland Clinic Lerner Research
te, Cleveland, Ohio.
isclosure: See Acknowledgments on page 1745.
dence and reprint requests: Brian T. Hill, MD, PhD,
land Clinic Taussig Cancer Institute, Hematologic On-
y and Blood Disorders, Cleveland, OH 44195 (e-mail:
@ccf.org).
ebruary 10, 2010; accepted June 6, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.06.009hematologic malignancies [2-5]. The best outcomes
occur when the second transplant is performed for
graft failure, with estimated survival rates of 30%-
37% after 3 years [6-11]. For patients who exhibit
graft failure after umbilical cord SCT, results appear
less favorable with a reported 2-year survival of
24% [3].
The largest published series of patients with re-
lapsed acute leukemia after autologous SCT showed
superior 2-year survival for patients who underwent
second transplant compared to those treated with che-
motherapy alone [12]. Younger age and longer interval
between transplants were associated with better
survival in multivariate analysis. Radich et al. [5] re-
ported the outcomes of 59 adult and pediatric patients
with relapsed hematologic malignancy after autolo-
gous transplantation. Univariate analysis demon-
strated that superior disease-free survival (DFS) was
associated with age\17 years at the time of the second
transplantation, remission before the second trans-
plantation, total body irradiation (TBI)-based pre-
parative regimen for the second transplant, and
a diagnosis of acute myelogenous leukemia (AML).
The probabilities of nonrelapse mortality (NRM),
Biol Blood Marrow Transplant 16:1738-1746, 2010 1739NMA Second Transplants Compared to MA Second Transplantsrelapse, and DFS, 2 years after second transplant, were
51%, 26%, and 23%, respectively.
Performing a repeat myeloablative (MA) allogeneic
transplant clearly carries high risk of NRM. For
patients with relapsed leukemia after initial allogeneic
transplant, performing a second allogeneic transplant
is associatedwithNRMbetween42%and46%at5years
[2,13]. In studies fromtheEuropeanCooperativeGroup
for Bone Marrow Transplant and the International
Bone Marrow Registry, young age, longer duration of
remission after first transplant, and complete remission
(CR) at the time of second transplant were associated
with improved survival.
Because of the high NRM rates of second MA
transplants, nonmyeloablative (NMA) conditioning
regimens have been utilized to improve outcomes.
Shaw et al. report NRM of 27% at 2 years for 71 pa-
tients who underwent reduced-intensity conditioning
(RIC) for relapsed hematologic malignancy after an
initial allogeneic transplant [4].
We retrospectively analyzed results of second
transplants using allogeneic donors to determine
whether NRM, relapse, and overall survival (OS) dif-
fered significantly between MA and NMA groups.
We defineNMA transplantation as those utilizing pre-
parative regimens that have been demonstrated to not
directly result in complete loss of recipient hematopoi-
esis. We used univariate and multivariate analyses to
determine prognostic factors.METHODS AND MATERIALS
Patient Population
Ninety-eight adult patients ($18 years old) who
underwent a second SCT from May 1987 to October
2008, after prior allogeneic or autologous SCT, wereTable 1. Second Transplant Preparative Regimens
Regimen Bu (mg/kg) TBI (cGy) Flu
MA (59)
Bu-Cy (10) 12.8 i.v. or 16 p.o. —
Bu-Cy-VP (14) 11.2 i.v. or 14 p.o. —
VP-TBI (8) — 1320
Cy-TBI (13) — 1200
Cy-ATG (8) — —
Other MA* (6)
NMA (39)
Flu-TBI 100 (1) — 100
Flu-TBI 200 (11) — 200
Flu-TBI 300 (1) — 300
Flu-TBI 400 (16) — 400
ATG (5)
Other NMA† (5)
Bu indicates busulfan; TBI, total-body irradiation; Flu, fludarabine; Cy, cyclop
intravenously; p.o., orally; MEDI507, experimental anti-CD2 monoclonal antib
*Other MA include 2 patients who received preparative regimen of Cy al
Bu-Cy-thiotepa, Bu-Cy-thioptepa, Bu-ATG, TBI-VP-ATG.
†Other NMA includes 1 patient each who received the following preparative re
and TBI-MEDI507 alone.identified from the Unified Transplant Database of
the Cleveland Clinic Taussig Cancer Institute. All pa-
tients were treated on protocols approved by the insti-
tutional review board of the Cleveland Clinic and gave
written informed consent.Second Transplant Regimens
Second transplant regimens are detailed in Table 1.
All hospitalized patients stayed in a dedicated inpatient
unit in laminar airflow rooms with standard infection
control procedures. Graft-versus-host disease (GVHD)
prophylaxis consisted of a combination of mycopheno-
late mofetil and cyclosporine or tacrolimus and meth-
otrexate, with or without corticosteroids.Classification of Acute Leukemia
We classified acute leukemia as AML, acute lym-
phoblastic leukemia (ALL), and chronic myelogenous
leukemia (CML) in blast crisis.
Statistical Analysis
The primary study variables were compared be-
tweenMA and NMA second transplants using Fisher’s
exact test (categoric variables) or the Wilcoxon rank
sum test (continuous variables). Outcomes were calcu-
lated relative to the date of second transplant, until the
event of interest, or until the date of last follow-up.
Relapse and NRM were estimated using the cumula-
tive incidence method and compared between MA
and NMA transplants using the Pepe-Mori test. Sur-
vival was estimated using the Kaplan-Meier test and
compared between MA and NMA transplants using
the log-rank test. Cox proportional hazard analysis
was used to identify univariate and multivariate risk
factors for relapse, NRM, and mortality. For the mul-
tivariate analysis, stepwise analysis was used with(mg/m2) Cy (mg/kg) VP (mg/kg) ATG (mg/kg)
— 120 — —
— 120 50 —
— — 50 —
— 120 — —
— 200 — 150
90 — — —
90 — — —
90 — — —
90 — —
150
hosphamide; VP, etoposide (VP-16); ATG, antithymocyte globulin; i.v.,
ody.
one and 1 patient who received the following preparative regimens:
gimens: Flu/alemtuzumab, alemtuzumab alone, Flu-Cy, Cy-TBI-MEDI507,
Table 2. Characteristics of Patients Who Received MA and NMA Second Transplant
MA (n 5 59) NMA (n 5 39)
Characteristic Number (%) Number (%) P
Age at second transplant, years, median (range) 34 (18-56) 45 (21-63) <.001
Male 32 (54.2) 24 (61.5) 0.54
KPS #80 (n 5 55 for MA, 26 for NMA) 12 (23.5) 9 (30.0) 0.60
First transplant type <.001
Autologous 23 (39.0) 25 (64.1)
Allogeneic 36 (61.0) 14 (35.9)
Preparative regimen for first transplant .12
Busulfan-based 52 (88.1) 30 (76.9)
TBI-based 4 (6.8) 6 (15.4)
Other 3 (5.1) 3 (7.7)
Time between first and second transplant
Median time in months (range) 10.6 (0.9-129) 16.2 (0.9- 193) .027
<3 months 11 (18.6) 6 (15.4)
>3 months 48 (81.4) 33 (84.6) 0.79
Diagnosis for second transplant <.001
Acute leukemia
AML 22 (37.3) 6 (15.4)
ALL 12 (20.3) 1 (2.6)
CML in blast crisis 2 (3.4) 1 (2.6)
Other
CML, chronic phase or remission 9 (10.2) 5 (12.8)
NHL 6 (10.2) 9 (23.1)
MDS 6 (10.2) 4 (10.2)
HL 4 (6.8) 5 (12.8)
Myeloma 0 7 (18.0)
Myeloproliferative neoplasm 0 1 (2.6)
CLL 1 (1.7) 0
Aplastic anemia 1 (1.7) 0
Same diagnosis for first and second transplant 51 (86.4) 34 (87.2) 1.0
Disease status at second transplant 1.0
CR 14 (23.7) 9 (23.1)
<CR 45 (76.3) 30 (76.9)
Donor relationship for second transplant 0.68
Related 32 (54.2) 23 (59.0)
Unrelated 27 (45.8) 16 (41.0)
Preparative regimen for second transplant <.001
Busulfan-based 24 (40.6) 0
TBI-based 22 (37.3) 31 (79.5)
Other 13 (22.0) 3 (20.5)
CD34+ dose, median, 106/kg (range),
(n 5 44 for MA, 33 for NMA)
2.7 (0.7-15.0) 5.6 (0.4-11.9) <.001
Length of hospital stay in days, median, days
(range), (n 5 59 for MA, 8 for NMA)
32 (8-109) 25 (11-110) —
Time until PMN >500/mL, median, days (range),
(n 5 47 for MA, 20 for NMA)
15 (0-40) 10 (0-30) 0.004
Time until platelet count >20,000/mL, median,
days, (range) (n 5 33 for MA, 18 for NMA)
22 (11-78) 13 (6-159) .021
Worst episode of acute GVHD —
None 20 (33.9) 20 (51.3)
Grade I 8 (13.6) 4 (10.3)
Grade II 14 (23.7) 6 (15.4)
Grade III 9 (15.3) 4 (10.3)
Grade IV 9 (13.6) 5 (12.8)
Worst episode of chronic GVHD
None 41 (69.5) 25 (64.1) —
Limited 5 (8.4) 45 (112.8)
Extensive 13 (22.0) 9 (27.3)
Secondary malignancy 2 (3.4) 3 (7.7) —
Follow-up among living patients, median,
months (range)
72.9 (12.9-136.4) 36.1 (7.1-83.6) .17
KPS indicates Karnofsky performance status; TBI, total body irradiation; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML,
chronic myelogenous leukemia; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; HL, Hodgkin lymphoma; CLL, chronic lymphocytic leu-
kemia; CR, complete remission; PMN, polymorphonuclear cells; GVHD, graft-versus-host disease; MA, myeloablative; NMA, nonmyeloablative.
1740 Biol Blood Marrow Transplant 16:1738-1746, 2010B. T. Hill et al.a variable entry criterion of P \ .10 and a variable
retention criterion of P\ .05. Cox analyses are sum-
marized as the hazard ratio (HR), 95% confidence in-
terval (CI) for the HR, and the corresponding P-value.All analyses were done using SAS software (SAS
Institute Inc., Cary, NC). All statistical tests were 2-
sided, and P \ .05 was used to indicate statistical
significance.
Table 3. Outcomes of MA and NMA Second Transplant
MA (n 5 59) NMA (n 5 8)
Characteristic Number (%) Number (%) P
Cumulative incidence of:
Relapse 15 (25.4) 18 (46.2) 0.12
Nonrelapse mortality 36 (61.0) 16 (41.0) 0.16
Death 53 (90.6) 24 (61.5) <.001
Survival, median, months 3.2 14.7 <.001
Cause of death (n 5 53 for
MA, n 5 24 for NMA)
—
Relapse 17 (32.1) 8 (33.3)
Acute GVHD 11 (20.8) 4 (16.7)
Chronic GVHD 6 (11.3) 3 (12.5)
Infection 6 (11.3) 0
Pulmonary toxicity 3 (5.7) 3 (12.5)
Nonpulmonary
organ failure
5 (9.4) 0
Graft failure 2 (3.8) 2 (8.3)
Cardiac 1 (1.9) 1 (4.2)
Secondary malignancy 1 (1.9) 1 (4.2)
Brain herniation 1 (1.9) 0
CNS hemorrhage 0 1 (4.2)
Unknown 1 (1.9) 0
MA indicates myeloablative; NMA, nonmyeloablative; GVHD, graft-
versus-host disease; CNS, central nervous system.
Figure 1. Kaplan-Meier estimates of relapse, NRM, and OS after MA
(thick lines) and NMA (thin lines) second transplant.
Biol Blood Marrow Transplant 16:1738-1746, 2010 1741NMA Second Transplants Compared to MA Second TransplantsRESULTS
Patient Characteristics
The characteristics of the 98 consecutive patients
who underwent MA or NMA second transplants are
summarized in Table 2. The median age of patients
who underwent MA second transplant was 34 years
(range: 18-56 years) compared to 45 years (range: 21-
63 years) for patients who underwent NMA second
transplant (P\ .001). There were comparable distri-
butions of males and females in both groups. Twelve
of 59 (23.5%) patients who underwent MA second
transplant had a Karnofsky performance status (KPS)
of 80 or lower, compared to 9 of 39 (30.0%) of patients
who underwent NMA second transplant (P 5 .60).
Thirty-six of 59 (61%) patients who underwent MA
second transplant had undergone allogeneic first trans-
plant, compared to 14 of 39 (35.9%) patients who un-
derwent NMA second transplant (P\ .001). The use
of busulfan (Bu) and TBI during first transplant was
similar in both groups. The median time from first
transplant to MA second transplant was shorter (10.6
months [range: 0.9-129 months]) than the time from
first transplant to NMA second transplant (16.2
months [range: 0.9-193], P 5 .027). Thirty-six of 59
(61.0%) patients who underwent MA second trans-
plant had a diagnosis of acute leukemia, compared to
8 of 39 (20.5%) patients who underwent NMA second
transplant (P\ .001). The indication for second trans-
plant was the same as for first transplant in a significant
majority of cases. Donor type and disease status at the
time of second transplant did not differ significantly
between groups.Second Transplant Characteristics
Characteristics of second transplant procedures
are also shown in Table 2. The median number of
CD341 cells infused during MA second transplant
was 2.7  106 cells/kg (range: 0.7-15.0) compared to
5.6 106 cells/kg (range: 0.4-11.9) for patients under-
going NMA SCT (P\ .001). All patients who under-
went MA second transplant required continuous
hospitalization whereas only 8 of 39 (20.5%) patients
Figure 2. Top panel: Kaplan-Meier estimates of OS after myeloablative
(MA) and nonmyeloablative (NMA) second transplant for patients with
acute leukemia (thick lines) and diagnoses other than acute leukemia
(thin lines). Bottom panel. Kaplan-Meier estimates of OS MA and
NMA second transplant for patients who underwent prior autologous
(thick lines) or allogeneic (thin lines) transplant.
1742 Biol Blood Marrow Transplant 16:1738-1746, 2010B. T. Hill et al.who underwent NMA second transplant were hospi-
talized during the transplant period. Recipients of
NMA second transplant required shorter periods of
hospitalization (median of 25 days [range: 11-110])
compared to patients who underwent MA second
transplant (median of 32 days [range: 8-109]). Patients
who underwent NMA second transplant also had
a shorter time to achieve a polymorphonuclear cell
count of 500 cells/mL (10 days [range: 0-30] versus
15 days [range: 8-40], P = 0.004) and platelet count
of 20,000 cells/mL (13 days [range: 0-159] versus 22
days [range: 11-78], P 5 .021). The incidences of
both acute and chronic GVHD (aGVHD, cGVHD)
was comparable in both groups. The two groups also
had similar incidences of secondary malignancies and
comparable duration of follow-up.
Second Transplant Regimens
Twenty-four of 59 (40.6%) patients who under-
went an MA second transplant received a Bu-based
preparative regimen compared to none of the patients
who underwent an NMA second transplant. Thirty-
one of 39 (79.5%) patients who received an NMA
second transplant received a TBI-based preparative
regimen, compared to 22 of 59 (37.3%) patients who
received an MA second transplant (P\ .001). Prepar-
ative regimens for MA and NMA transplants are
shown in Table 1. Bu was used at a cumulative dose
of 11.2 or 12.8 mg/kg intravenously (i.v.) (14 or 16
mg/kg orally [p.o.]) depending on whether or not it
was combined with VP16. MA TBI doses were 1200
or 1320 cGy. The NMA dose of TBI was in the range
of 100-400 cGy in combination with fludarabine 90
mg/kg. It has previously been demonstrated that
a regimen utilizing TBI 400 cGy combined with
fludarabine 90 mg/m2 is NMA [14].
Mortality and Disease Relapse after MA and
NMA Second Transplant
The incidences of disease relapse, NRM, and mor-
tality after second transplant are shown in Table 3.
Patients who underwent MA second transplant experi-
enced less disease relapse than those who underwent
NMA second transplant (25.4% versus 46.2%, P 5
0.12). NRM was higher for patients who underwent
MA second transplant compared to patients who un-
derwent NMA second transplant (61.0% versus
41.0%, P 5 .16). NRM and overall mortality were
both higher for patients who underwent MA second
transplant compared to patients who underwent
NMA second transplant (61.0% vs 41.0%, P 5 0.16
for NRM and 89.8 vs. 61.5%, P\ 0.001 for death).
The median survival of patients who underwent MA
second transplant was 3.2 months, compared to 14.7
months for patient who underwent NMA second
transplant (P\ .001). Causes of death after MA andNMA second transplant are shown. Estimates of re-
lapse, NRM, andOS after second transplant are shown
in Figure 1.
Outcomes Stratified by Initial Diagnosis and
Type of Second Transplant
We analyzed patient outcomes by diagnosis at the
time of first transplant as well as by type of second
transplant. Patients who underwent NMA second
transplant for a diagnosis of acute leukemia experi-
enced higher relapse rates, but also a trend toward su-
perior OS relative to patients with acute leukemia who
underwent MA second transplant (Figure 2) (P \
0.001). This trend for superior overall survival is
similar for patients with acute leukemia (P 5 0.38).
Outcomes Stratified by Type of First Transplant
and Type of Second Transplant
For patients who underwent autologous first trans-
plant, NMA second transplant was associated with an
improvement in OS relative to MA second transplant
Table 4. Univariate Risk Factors for Relapse, NRM, and Mortality
Relapse NRM Mortality
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age at transplant (years)
per 10 year increase 1.20 (0.92-1.58) .17 0.93 (0.75-1.16) .53 0.97 (0.81-1.16) .73
Sex
Male/female 1.15 (0.58-2.29) .68 1.12 (0.65-1.94) .68 1.19 (0.76-1.88) .44
KPS (n 5 82)
30-70/100 3.81 (0.66-21.9) .13 2.60 (0.93-7.24) .07 3.03 (1.23-7.48) .016
80/100 1.40 (0.35-5.64) .63 1.03 (0.39-2.70) .96 1.35 (0.59-3.06) .48
90/100 2.45 (0.81-7.41) .11 1.46 (0.69-3.07) .32 1.96 (1.02-3.78) .044
Preparative regimen for first transplant
TBI/busulfan 1.24 (0.43-3.59) .69 0.49 (0.15-1.58) .23 0.81 (0.37-1.76) .59
Other/busulfan 2.06 (0.62-6.86) .24 0.96 (0.30-3.10) .95 0.92 (0.34-2.54) .88
First transplant type
Auto/MA 2.21 (0.98-4.98) .06 0.67 (0.38-1.16) .15 0.71 (0.45-1.12) .14
Donor relationship for second transplant
Unrelated/related 1.01 (0.50-2.06) .98 1.50 (0.87-2.59) .14 1.31 (0.83-2.06) .24
Second transplant type
MA/NMA 0.75 (0.42-1.65) 0.60 2.24 (1.73-6.63) 0.008 2.30 (1.42-3.74) <.001
Time between transplants
#3 months/>3 months — — 4.10 (2.22-7.60) <.001 2.97 (1.69-5.22) <.001
Disease status at second transplant
<CR/CR 3.22 (1.12-9.27) .031 1.18 (0.62-2.25) .62 1.22 (0.72-2.08) .46
Preparative regimen for second transplant
TBI/busulfan 0.63 (0.29-1.34) .23 0.69 (0.35-1.35) .28 0.51 (0.30-0.85) .011
Other/busulfan 0.52 (0.14-1.91) .33 1.65 (0.76-3.56) .21 1.14 (0.60-2.15) .69
CI indicates confidence interval; NRM, nonrelapse mortality; TBI, total body irradiation; KPS, Karnofsky performance status; Auto, autologous stem cell
transplant; MA, myeloablative; NMA, nonmyeloablative; CR, complete remission; HR, hazard ratio.
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not statistically significant for those patients who un-
derwent allogeneic first transplant (P 5 0.62).Prognostic Variables
Univariate risk factors for relapse, NRM, and over-
all mortality are shown in Table 4. Factors not
associated with any of these outcomes included patient
age, sex, preparative regimen for first transplant, first
transplant type, and donor relationship for second
transplant. In univariate Cox analysis, the only prog-
nostic factor identified for relapse was disease status;
patients not in CR at the time of second transplant
were at increased risk of relapse relative to patients in
CR at the time of second transplant (HR of 3.22,Table 5. Multivariable Risk Factors for Relapse, NRM, and Mortalit
Relapse
HR (95% CI) P
Second transplant type
MA/NMA 0.42 (0.15-1.18) 0.10
Time between transplants
#3 months/>3 months — —
Disease status at second transplant
<CR/CR 4.87 (1.58-15.04) .006
Preparative regimen for second transplant
TBI/busulfan 0.20 (0.05-0.59) .008
Other/busulfan 0.36 (0.09-1.42) .14
Auto indicates autologous stem cell transplant; MA, myeloablative; NMA, nonm
complete remission; CI, confidence interval; HR, hazard ratio.P 5 .031). Disease status was not associated with
NRM or death. Relative to NMA second transplant,
MA second transplant was associated with increased
risk of NRM (HR 2.24, P 5 0.008) and death (HR
2.30, P\ .001). Likewise, an interval between trans-
plants of\3 months was also associated with an in-
creased risk of NRM (HR 4.10, P\ .001) and death
(HR 2.97, P\ .001). Additionally, in univariate analy-
sis, patients who received a TBI-based second trans-
plant regimen had lower risk of mortality than those
who received a Bu-based regimen (HR 0.51, P5 .011).
Multivariate risk factors for relapse, NRM, and
mortality are shown in Table 5. MA second transplant
conferred less risk of relapse (HR 0.42, P5 .10), but an
increased risk of NRM (HR 2.01, P5 0.022) and death
(HR 2.13, P 5 .002) when compared to NMA secondy
NRM Mortality
HR (95% CI) P HR (95% CI) P
2.01 (1.10-3.65) 0.022 2.13 (1.30-3.47) 0.002
3.71 (2.00-6.89) <.001 2.61 (1.49-4.59) <0.001
— — — —
— — — —
yeloablative; NRM, nonrelapse mortality; TBI, total body irradiation; CR,
Table 6. Characteristics of PatientsWhoUnderwent Second
Transplant within 3 Months and after 3 Months of First
Transplant
<3 months (n 5 17) >3 months (n 5 81)
Number (percent) Number (percent) P
Type of transplant
Myeloablative 11 (64.7) 48 (59.3) —
Incidence of <.001
Relapse 0 33 (40.7)
NRM 16 (94.1) 36 (44.4)
Death 17 (100) 60 (74.1)
Median survival,
months
2.3 10.6 <.001
NRM indicates nonrelapse mortality.
1744 Biol Blood Marrow Transplant 16:1738-1746, 2010B. T. Hill et al.transplant. Patients not in CR at the time of second
transplant had increased risk of relapse (HR 4.87,
P 5 .006). Patients who underwent second transplant
within 3 months of first transplant were at an increased
risk of NRM (HR 3.71, P\ .001) and death (HR 2.61,
P\ .001) relative to patients whose interval between
transplants was longer than 3 months.
Second Transplants Performed within 3 Months
of First Transplant
Characteristics of outcomes for patients who un-
derwent second transplant within 3 months of first
transplant are shown in Table 6 and compared to the
outcomes of patients who underwent second trans-
plant more than 3 months after first transplant. Eleven
of 17 (64.7%) patients whose interval between trans-
plants was\3 months received an MA second trans-
plant. Forty-eight of 81 (59.3%) patients whose
interval between transplants exceeded 3 months re-
ceived MA second transplants. The remainder of pa-
tients received an NMA second transplant. For
patients whose interval between transplants was \3
months, the incidence of NRM and mortality were
94.1% and 100%, respectively. Median survival was
2.3 months. For patients whose interval between trans-
plants was .3 months the cumulative rates of relapse,
NRM, and mortality were 40.7%, 44.4%, and 74.1%,
respectively. Kaplan-Meier estimates of OS for pa-
tients whose interval between transplants was \3
months are shown in Figure 3 (top left panel).
We also assessed the outcomes of patients who
were transplanted .3 months after first transplant
based on whether the second transplant was MA or
NMA. As shown in Figure 3, patients who underwent
an NMA conditioning regimen more than 3 months
after first transplant had higher relapse rates but lower
NRM resulting in superior OS. Five-year survival esti-
mates were 23.4% among patients who transplanted
.3 months after first transplant, 13.1% among pa-
tients who underwent MA second transplant .3
months after first transplant, and 38.9% among pa-
tients who underwent NMA .3 months after the first
transplant (P\ .001).DISCUSSION
Allogeneic transplantation represents the only po-
tentially curative therapy for most patients who have
failed prior allogeneic or autologous transplant, but
it is performed infrequently because of its substantial
morbidity and mortality. To avoid this excessive toxic-
ity, NMA second transplantation has been utilized.
We describe here the largest series of patients in
whom a direct comparison can be made between the
outcomes of NMA second transplants and traditional
MA second transplants. There is limited evidencedemonstrating any setting in which NMA is superior
to MA transplant [15,16].
Our results confirm that MA second transplant is
associated with a remarkably high rate of NRM. The
incidence of NRM of 64.1% observed in this analysis
is similar to that observed by others [2,5,13]. The
lower incidence of NRM following NMA second
transplant more than offsets high relapse rates
resulting in improved OS.
Is it possible that the improved outcomes of pa-
tients who underwent NMA second transplant are be-
cause of inherent differences in the 2 groups of
patients? Patients who underwent MA second trans-
plant were more likely to have undergone prior alloge-
neic transplant. Importantly, the OS of patients who
underwent autologous first transplant was superior
for those whose second transplant was NMA. This dif-
ference favoring NMA second transplant was not
clearly observed for patients whose first transplant
was allogeneic, possibly due to the small numbers of
patients in these subgroups.
Patients in this study who underwent an MA sec-
ond transplant were more likely to have a diagnosis
of acute leukemia than those who underwent an
NMA second transplant. There was a statistically sig-
nificant improvement in overall survival of patients
without acute leukemia treated with an NMA second
transplant and a trend towards improved survival of
patients with acute leukemia. This difference was
statistically significant in favor of NMA second trans-
plants for patients with a diagnosis other than acute
leukemia.
Which patients are good candidates for NMA sec-
ond transplant? Several studies have identified young
age, long duration between transplants, and CR at
the time of second transplant as good-risk prognostic
factors for outcomes after second transplant
[2,3,5,12,13]. Our data identify duration between
transplants and disease status as predictors of relapse,
NRM, and death. Consistent with the Seattle
experience, a TBI-based second transplant regimen
was also favorable in univariate analysis [5]. Patient
age was not identified as a prognostic factor. These
Figure 3. Upper left panel: Kaplan-Meier estimates of OS after all patients undergoing second transplant more than 3 months after first transplant
(thick line) and fewer than 3 months after first transplant (thin line). Other panels: Kaplan-Meier estimates of relapse, NRM, and OS for patients un-
dergoing MA (thick lines) and NMA (thin lines) second transplant more than 3 months after first transplant.
Biol Blood Marrow Transplant 16:1738-1746, 2010 1745NMA Second Transplants Compared to MA Second Transplantsfactors should clearly be considered when evaluating
any individual patient for second transplant.
Special note should be made about short intervals
between transplants. Patients who undergo second
transplant within 3 months of failed first transplant
have a median survival of 2.3 months and almost
100% mortality at 1 year. It is our recommendation
that this group of patients should not receive an MA
second transplant. Extrapolating from the finding of
improved OS and decreased NRM after an NMA
second transplant, this approach should be considered
first-line therapy for all patients, particularly those
requiring treatment soon after original transplant.ACKNOWLEDGMENTS
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